nasir arefinia

Dr. nasir arefinia

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2025 in Cancer Epidemiology
Verified
Journal Article
Closed access
HMHabibeh Mashayekhi-Sardoo
Habibeh Mashayekhi-Sardoo
ZGZohreh-Al-Sadat Ghoreshi
Zohreh-Al-Sadat Ghoreshi
HAHedyeh Askarpour
Hedyeh Askarpour
NAnasir arefinia
nasir arefinia
MHMohammad Ali hassanzadeh
Mohammad Ali hassanzadeh

1 January 2023 in Cancer Informatics
Verified
Journal Article
Open access
MFMehdi Fazlalipour
Mehdi Fazlalipour
ZGZohreh-Al-Sadat Ghoreshi
Zohreh-Al-Sadat Ghoreshi
HMHamid Reza Molaei
Hamid Reza Molaei
NAnasir arefinia
nasir arefinia
This review discusses the possible involvement of infections-associated cancers in humans, with virus infections contributing 15% to 20% of total cancer cases in humans. DNA virus encoded proteins interact with host cellular signaling pathways and control proliferation, cell death and genomic integrity viral oncoproteins are known to bind cellular Deubiquitinates (DUBs) such as cyclindromatosis tumor suppressor, ubiquitin-specific proteases 7, 11, 15 and 20, and A-20 to improve their intracellular stability and cellular signaling pathways and finally transformation. Human papillomaviruses (cervical carcinoma, oral cancer and laryngeal cancer); human polyomaviruses (mesotheliomas, brain tumors); Epstein-Barr virus (B-cell lymphoproliferative diseases and nasopharyngeal carcinoma); Kaposi’s Sarcoma Herpesvirus (Kaposi’s Sarcoma and primary effusion lymphomas); hepatitis B (hepatocellular carcinoma (HCC)) cause up to 20% of malignancies around the world.

25 February 2025 in Health Science Reports
Verified
Journal Article
Open access
MNMohsen Nakhaie
Mohsen Nakhaie
MRMohammad Rezaei Zadeh Rukerd
Mohammad Rezaei Zadeh Rukerd
NFNiloofar Farsiu
Niloofar Farsiu
DBDavood Bashash
Davood Bashash
FMFatemeh Khodadadpour Mahani
Fatemeh Khodadadpour Mahani
FBFarzane Behnezhad
Farzane Behnezhad
Background and Aims: Monkeypox (Mpox), caused by the monkeypox virus (MPXV), has emerged as a significant global public health concern, particularly following a substantial multi‐country outbreak in mid‐2022. The World Health Organization (WHO) reported 109,699 laboratory‐confirmed Mpox cases and 236 fatalities worldwide from January 1, 2022, to September 30, 2024. This narrative review aims to evaluate the co‐infections of Mpox with various viral agents and assess their implications for public health.Methods: We conducted a comprehensive review of the literature regarding Mpox co‐infections with human immunodeficiency virus (HIV), severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), hepatitis viruses (hepatitis A virus (HAV), hepatitis B virus (HBV), and hepatitis C virus (HCV)), and herpesviruses (including herpes simplex virus (HSV)‐1, HSV‐2, varicella‐zoster virus (VZV), and cytomegalovirus (CMV)).Results: We analyzed epidemiological trends, clinical manifestations, preventive measures, treatment guidelines, and advanced diagnostic methodologies. The review highlights the intricate dynamics of Mpox co‐infections and underscores the necessity for comprehensive diagnostic approaches, including viral load assays, to evaluate active co‐infections, particularly for HIV and HBV.Conclusion: Understanding the interplay between MPXV and other viral pathogens is crucial for enhancing management strategies for co‐infections. By addressing these complexities, we aim to contribute valuable insights into the public health implications of Mpox co‐infections and improve response strategies.

3 May 2024 in Data in Brief
Verified
Journal Article
Open access
NAnasir arefinia
nasir arefinia
PBParsa Banafi
Parsa Banafi
MZMohammad Amin Zarezadeh
Mohammad Amin Zarezadeh
HMHawra Shah Mousawi
Hawra Shah Mousawi
RYRamin Yaghobi
Ramin Yaghobi
JSJamal Sarvari
Jamal Sarvari
The prognosis of COVID-19 could influence by innate immune sensors such as toll-like receptors (TLRs). The purpose of this data was to investigate TLR3, 7, and 8 expression levels in COVID-19 patients and their relationship to outcome of disease. 75 confirm COVID-19 were included sequentially and separated into three groups: mild, severe, and critical. Peripheral blood mononuclear cells were isolated from the whole blood, and RNA was then extracted. The qRT-PCR technique was used to examine the expression of TLR3, TLR7, and TLR8 genes. The patients average ages were 52.69 ± 1.9 and 13 of the 25 individuals in each group were male. TLR3 (p < 0.001), TLR7 (p < 0.001), and TLR8 (p < 0.001) expression levels were considerably greater in COVID-19 patients compared to the control group. The findings also showed that individuals with critical and severe COVID-19 disease had significantly greater TLR7 and TLR8 gene expression levels than patients in mild stage of disease (p < 0.05). The data showed a significant difference (p = 0.01) in the TLR3 transcript levels between critical and mild COVID-19 patients. Furthermore, male severe (p = 0.02) and critical (p = 0.008) patients had significantly higher TLR8 expression levels than female patients in terms of gender. TLR3 (p = 0.2) and TLR7 (p = 0.08) transcripts were more elevated in males than females, but not significantly.

18 April 2022 in Journal of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
ZGZohreh-Alsadat Ghoreshi
Zohreh-Alsadat Ghoreshi
MNMohsen Nakhaee
Mohsen Nakhaee
MSMohammad Samie
Mohammad Samie
MZMohsen Sharif Zak
Mohsen Sharif Zak
NAnasir arefinia
nasir arefinia
Innate immune receptors detect nucleic acids, such as viruses, and initiate an immune response by secreting interferon (IFN) and regulating IFN-stimulated genes (ISG). in autoimmune conditions, expression of ISGs funded, show the activation of nucleic acid sensory pathways. However, the nucleus-localized innate sensors are recently found to detect pathogenic nucleic acids for initiating innate response, demonstrating a complicated crosstalk with cytoplasmic sensors and signaling molecules to form an elaborate tiered innate signaling network between nucleus and cytoplasm. to sustain immune hemostasis, these innate immune sensors develop different strategies for discriminating between self or non-self-nucleic acid. We reviewed all the sensors involved in the innate immune system in the present study. A better understanding of these sensors can lead to new treatments for infections, cancer, and autoimmune and inflammatory disorders.

13 October 2022 in International Wound Journal
Verified
Journal Article
Open access
NAnasir arefinia
nasir arefinia
ZGZohreh Al‐Sadat Ghoreshi
Zohreh Al‐Sadat Ghoreshi
AAAmir Hossein Alipour
Amir Hossein Alipour
BIBehzad Iranmanesh
Behzad Iranmanesh
NMNiloofar Mehrolhasani
Niloofar Mehrolhasani
JSJamal Sarvari
Jamal Sarvari
The systemic and respiratory clinical manifestations of coronavirus disease 2019 (COVID‐19) include fever, coughing, sneezing, sore throat, rhinitis, dyspnea, chest pain, malaise, fatigue, anorexia and headache. Moreover, cutaneous manifestations have been reported in 0.2% to 20.4% of cases. Early diagnosis of COVID‐19 leads to a better prognosis; knowledge of its cutaneous manifestations is one way that may help fulfil this goal. In this review, PubMed and Medline were searched with the terms “dermatology”, “skin” and “cutaneous”, each in combination with “SARS‐CoV‐2” or “COVID‐19”. All articles, including original articles, case reports, case series and review articles published from the emergence of the disease to the time of submission, were included. In this comprehensive narrative review, we tried to provide an analysis of the cutaneous manifestations associated with COVID‐19, including maculopapular rash, urticaria, Chilblain‐like, vesicular lesions, livedo reticularis and petechiae in asymptomatic/symptomatic COVID‐19 patients that might be the first complication of infection after respiratory symptoms. Immune dysregulation, cytokine storms, side effects of antiviral drugs, environmental conditions and high‐dose intravenous immunoglobulin (IVIG) therapy might be involved in the pathogenesis of the cutaneous manifestations in COVID‐19 patients. Therefore, knowledge of cutaneous COVID‐19 manifestations might be vital in achieving a quick diagnosis in some COVID‐19 patients, which would help control the pandemic. Further research is very much warranted to clarify this issue.